Trials / Completed
CompletedNCT00372437
A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 47 (actual)
- Sponsor
- Mirati Therapeutics Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Inthis study, MGCD0103, a new anticancer drug under investigation, is given three times weekly in combination with gemcitabine to patients with solid tumours.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MGCD0103 | MGCD0103 as an oral dose three times per week. |
| DRUG | Gemcitabine | Gemcitabine 1000mg/m\<2\> intravenously days 1, 8, 15 of a 28 day cycle. |
Timeline
- Start date
- 2006-09-01
- Primary completion
- 2008-12-01
- Completion
- 2008-12-01
- First posted
- 2006-09-07
- Last updated
- 2015-07-01
Locations
8 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00372437. Inclusion in this directory is not an endorsement.